Extension of Time to File SOU

PTO- 1581

Approved for use through 12/31/2020. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1581

Approved for use through 12/31/2020. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: RSM (see, http://uspto.report/TM/88129597/mark.png)
SERIAL NUMBER: 88129597

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Finch Therapeutics, Inc., having an address of
      200 Inner Belt Road, Suite 400
      Somerville, Massachusetts 02143
      United States
      Email: XXXX
Proposed: Finch Therapeutics, Inc., having an address of
      200 Inner Belt Road, Suite 400
      Somerville, Massachusetts 02143
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 01/29/2019.

For International Class 005:
Current identification: Pharmaceuticals used to maintain health or restore health to a human or animal subject via treatment of a disturbed microbial community; dietary and nutritional supplements; nutritional food additives in the nature of dietary supplements for medical purposes; diagnostic agents for medical purposes for assessing whether a human or animal subject has a disturbed microbial community; biological preparations in the nature of microorganisms used to maintain health or restore health to a human or animal subject via treatment of a disturbed microbial community; cultures and preparations of microorganisms for medical and veterinary purposes; pharmaceutical and biopharmaceutical agents, namely, microbiologics, immunotherapeutics, and other therapeutic agents for the prevention and treatment of human diseases, namely, infectious disease, autoimmune disease, inflammatory disease, immune disorders, allergic disorders, cancer, immuno-oncology, metabolic disorders, digestive disorders, neurological disorders, and cardiovascular disorders; pharmaceuticals in the nature of cultures of microorganisms for medical and veterinary use

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the fourth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development

Correspondence Information (current):
      Rachelle A. Dubow, Esquire
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@morganlewis.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rachelle.dubow@morganlewis.com; brittany.estell@morganlewis.com; jennifer.kagan@morganlewis.com

Correspondence Information (proposed):
      Rachelle A. Dubow, Esquire
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@morganlewis.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rachelle.dubow@morganlewis.com; brittany.estell@morganlewis.com; jennifer.kagan@morganlewis.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Benjamin Enerson/      Date Signed: 01/28/2021
Signatory's Name: Benjamin Enerson
Signatory's Position: General Counsel
Signature method: Sent to third party for signature

PAYMENT: 88129597
PAYMENT DATE: 01/28/2021

Serial Number: 88129597
Internet Transmission Date: Thu Jan 28 16:49:11 ET 2021
TEAS Stamp: USPTO/ESU-XXX.XXX.XXX.XX-202101281649114
02332-88129597-760113c6a785065f5fd30f2d2
80dfeb3fa7e7b9782e72d28fba157326193c5b26
-DA-49091078-20210125110425853758